Common use of Non-Respiratory Alliance Products Clause in Contracts

Non-Respiratory Alliance Products. In the event that GSK terminates Commercialization of an Alliance Product under Section 14.4 and such Alliance Product is a Non-Respiratory Alliance Product (hereinafter "Terminated Non-Respiratory Commercialized Alliance Product"), and provided that such Terminated Non-Respiratory Commercialized Alliance Product is not being or has not been replaced by an alternative Non-Respiratory Alliance Product, the following shall occur:

Non-Respiratory Alliance Products. In the event that GSK terminates Commercialization Development of an Alliance Product under Section 14.4 14.3 and such Alliance Product is a Non-Respiratory Alliance Product (hereinafter "Terminated Non-Respiratory Commercialized Development Alliance Product"), and provided that such Terminated Non-Respiratory Commercialized Development Alliance Product is not being or has not been replaced by an alternative Non-Respiratory Development Alliance Product, the following shall occuroccur in respect of such Terminated Non-Respiratory Development Alliance Product:

Non-Respiratory Alliance Products. In the event that GSK terminates Commercialization of an Alliance Product under Section 14.4 and such Alliance Product is a Non-Respiratory Alliance Product (hereinafter "“Terminated Non-Respiratory Commercialized Alliance Product"”), and provided that such Terminated Non-Respiratory Commercialized Alliance Product is not being or has not been replaced by an alternative Non-Respiratory Alliance Product, the following shall occur:

Non-Respiratory Alliance Products. In the event that GSK terminates Commercialization Development of an Alliance Product under Section 14.4 14.3 and such Alliance Product is a Non-Respiratory Alliance Product (hereinafter "“Terminated Non-Respiratory Commercialized Development Alliance Product"”), and provided that such Terminated Non-Respiratory Commercialized Development Alliance Product is not being or has not been replaced by an alternative Non-Respiratory Development Alliance Product, the following shall occuroccur in respect of such Terminated Non-Respiratory Development Alliance Product:

Non-Respiratory Alliance Products. In the event that GSK terminates Commercialization Development of an Alliance Product under Section 14.4 14.3 and such Alliance Product is a Non-Respiratory Alliance Product (hereinafter "Terminated Non-Respiratory Commercialized Development Alliance Product"), and provided that such Terminated Non-Respiratory Commercialized Development Alliance Product is not being or has not been replaced by an alternative Non-Respiratory Development Alliance 50 Product, the following shall occuroccur in respect of such Terminated Non-Respiratory Development Alliance Product: